ABSTRACT BACKGROUND In patients undergoing percutaneous coronary intervention (PCI), drug-eluting stents (DES) reduce
C oronary heart disease affects 30% to 60% of patients with end-stage renal disease (ESRD) on dialysis (1) (2) (3) , and the number of such patients undergoing percutaneous coronary intervention (PCI) has increased by nearly 50% over the past decade (4) . Numerous clinical trials in patients with preserved kidney function demonstrate that drug-eluting stents (DES) reduce repeat revascularizations compared with bare-metal stents (BMS), but effects on the risk of myocardial infarction (MI) and mortality are less consistent (5, 6) . A metaanalysis of 76 randomized clinical trials comparing DES and BMS showed that short-term risk of MI was reduced in DES relative to BMS, but with no benefit on short-term mortality (5) .
Pooled analysis of data from 3 randomized trials showed similar results consistently across different levels of kidney function, although patients with ESRD were excluded (6) .
Current guidelines recommend using DES rather than BMS in patients with ESRD (7), based on extrapolation of data from patients with normal or near-normal kidney function.
However, uremia, inflammation, or dialysis itself may lead patients with ESRD to have more diffuse coronary disease and more vascular calcification (1), making them more prone to post-procedural complications than are patients without ESRD (8) .
There has been only 1 randomized clinical trial directly comparing DES with BMS that did not explicitly exclude patients with ESRD on dialysis, and it showed lower rates of target vessel revascularization at 12 months with DES (9) . Only 22 participants in that trial had ESRD, and 1-year mortality was much lower than the national annual death rate. Those results may therefore not be generalizable to the overall ESRD population. Observational studies have yielded mixed results; some show a benefit of DES over BMS (8, 10) , whereas others do not (11) (12) (13) (14) (15) (16) (17) . Many of the studies involved small cohorts, were in largely Asian populations, or did not adequately adjust for potential confounders-perhaps accounting for some of the heterogeneity in outcomes.
Despite the paucity of evidence, use of DES rose rapidly in ESRD patients after approval of the first showing longer-term benefit and safety of DES (25) .
DES in the United
We studied patients with ESRD on maintenance ( Figure 1 ) and through December 31, 2010.
For patients with multiple PCI, the first recorded PCI was the index PCI. We required that patients have continuous Medicare parts A and B coverage as primary payer for at least 6 months prior to the index hospitalization admission date to allow determination of baseline comorbid conditions. Patients undergoing any type of heart surgery during the index hospitalization were excluded, as were patients who received both BMS and DES or who had no record of stent placement during the index PCI. All patients were required to be on maintenance dialysis during the index PCI, per USRDS-defined modality file (rxhist60).
FOLLOW-UP AND OUTCOMES. We examined 3 outcomes within 1 year after index PCI: 1) death from any cause; 2) death or MI; and 3) death, MI, or repeat revascularization (Online Table 1 We defined comorbid conditions using International Classification of Diseases-Ninth Edition diagnosis and procedure codes requiring at least 1 inpatient or 2 outpatient encounters separated by $1 day using all available historical data prior to (but not including) the index date (Online Table 1 Was not on dialysis during index PCI: n = 6,097 n = 48,009
Stent received prior to DES approval: n = 11,892
Final Cohort n = 36,117
Assembly of cohort of patients with end-stage renal disease (ESRD) on dialysis who underwent percutaneous coronary intervention (PCI) with stenting after drug-eluting stents (DES) became available in the United States. BMS ¼ bare-metal stent(s).
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Stent Type and Outcomes in Dialysis Abbreviations as in Table 1 .
Stent Type and Outcomes in Dialysis used to conduct inverse probability of treatment weighting (IPTW) estimation with stabilized weights (36, 37) . A strength of IPTW is that the entire cohort remains available for analysis and results are generalizable to the entire population from which the observed sample was derived, in contrast to propensity score matching, which necessarily excludes the unmatched portion of the cohort (32).
We estimated hazard ratios (HR) and corresponding 95% confidence intervals (CI) for outcomes of interest using proportional hazards regression models.
Because all baseline variables were well balanced (i.e., standardized differences <10.0) in the IPTW and propensity score-matched cohorts ( Table 1) , we made no further adjustments to the models. In the IPTW analyses, we used robust standard errors. We tested the proportionality assumption using Schoenfeld residual plots.
Given the possibility of residual confounding by indication, we conducted an analysis leveraging the temporal trends in DES use during the study period.
Rather than directly compare DES with BMS use, we divided the cohort into 3 distinct DES eras based on previous studies (26) 1) that DES era was associated with outcomes only through its association with receipt of DES or BMS;
and 2) that the instrumental variable randomizes patients such that patients are similar with respect to measured and unmeasured variables across levels of the instrument.
The institutional review board of Stanford University approved the study. All analyses were conducted using SAS Enterprise Guide (version 6.1, SAS Institute, Cary, North Carolina).
RESULTS

Overall, 36,117 patients on maintenance dialysis underwent PCI with stenting between 2003 and 2010
and passed inclusion and exclusion criteria ( Figure 1 ).
Sixty-nine percent of the final cohort received a DES.
Mean age was 64 years, and there was a high prevalence of diabetes, hypertension, and hyperlipidemia.
Patients who received DES had higher prevalence of diabetes mellitus, but patients who received BMS more often had a previous history of MI and more often presented with a ST-segment elevation MI (Table 1) .
DES VERSUS BMS.
In the logistic regression model on stent type (c ¼ 0.6; Hosmer and Lemeshow goodness-of-fit test, p ¼ 0.86) (Online Table 2 ), female sex, multivessel intervention, and presence of heart failure and diabetes mellitus were associated with higher odds of receiving a BMS versus DES. We matched 96% of BMS patients to a corresponding DES patient. All baseline variables were well balanced among patients receiving BMS and DES after propensity score matching and after applying the IPTW (Table 1) . Illustration) . These results were similar using the Chang et al. Hazard ratios comparing drug-eluting stents (DES) with bare-metal stents (BMS) after percutaneous coronary intervention in patients with end-stage renal disease on dialysis for the specified outcomes using 2 different analytical approaches. Error bars represent 95% confidence intervals (CI). MI ¼ myocardial infarction;
Revasc ¼ revascularization. Death log-rank p = 0.01
Death or MI log-rank p < 0.0001
Death, MI or RR log-rank p < 0.0001 
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